nglycan
releas
sar
coronaviru
sarscov
spike
glycoprotein
produc
vero
cell
structur
determin
combin
matrixassist
laser
desorptionion
maldi
mass
spectrometri
neg
ion
electrospray
collisioninduc
dissoci
timeofflight
mass
spectrometri
normalphas
highperform
liquid
chromatographi
exoglycosidas
digest
major
glycan
highmannos
man
glcnac
hybrid
bi
triand
tetraantennari
complex
without
bisect
glcnac
core
fucos
complex
glycan
fewer
full
complement
galactos
residu
present
sialyl
neglig
treatment
glucosidas
inhibitor
nbutyldeoxynojirimycin
nbdnj
inhibit
nglycan
process
evidenc
appear
glycan
composit
glc
man
glcnac
howev
complex
glycan
remain
suggest
presenc
data
tissu
cultur
indic
inhibit
nglycan
process
may
consid
therapeut
strategi
sar
cov
infect
aetiolog
agent
sever
acut
respiratori
syndrom
sar
coronaviru
sarscov
respons
caus
worldwid
pandem
lower
respiratori
tract
infect
novemb
juli
ksiazek
et
al
marra
et
al
rota
et
al
time
approxim
probabl
sar
case
approxim
record
fatal
http
wwwwprowhointsar
rapid
identif
individu
present
diseas
well
appropri
nurs
techniqu
quarantin
procedur
allow
outbreak
control
juli
sinc
smaller
outbreak
diseas
contain
minim
secondari
transmiss
clinic
sarscov
infect
present
atyp
pneumonia
patient
report
symptom
high
fever
dri
cough
short
breath
dyspnea
andor
sever
breath
difficulti
may
occasion
requir
mechan
ventil
viral
reservoir
presum
bat
wang
eaton
wang
et
al
palm
civet
cat
implic
carrier
viru
though
may
also
asymptomat
anim
carrier
shi
hu
sever
protein
found
sar
coronaviru
tan
et
al
ying
et
al
larg
sarscov
spike
glycoprotein
tripet
et
al
locat
virion
surfac
involv
target
cell
attach
fusion
process
yang
et
al
sever
coronavirus
spike
glycoprotein
proteolyt
cleav
two
noncoval
associ
glycoprotein
virionassoci
amino
acid
residu
contain
receptor
attach
site
transmembraneanchor
residu
respons
fusion
activ
bergeron
et
al
folli
et
al
li
et
al
sarscov
glycoprotein
acid
precursor
polypeptid
deduc
publish
genom
sequenc
potenti
nlink
glycosyl
site
marra
et
al
rota
et
al
xiao
et
al
previou
studi
demonstr
sever
site
occupi
possess
complextyp
highmannos
type
nglycan
krokhin
et
al
song
et
al
ying
et
al
howev
full
glycan
analysi
yet
perform
sarscov
use
angiotensin
convert
enzym
primari
receptor
chen
subbarao
li
et
al
moor
et
al
wang
et
al
suggest
oligomannosecontain
nglycan
sarscov
glycoprotein
surfac
may
involv
mediat
viru
attach
cell
express
cell
surfac
lectin
ctype
lectin
dcsign
lsign
dclsign
enhanc
viral
entri
marzi
et
al
yang
et
al
sitedirect
mutagenesi
analys
identifi
seven
glycosyl
site
protein
critic
dclsignmedi
viru
entri
includ
asparagin
residu
distinct
residu
domain
amino
acid
han
et
al
recent
lsign
dcsignr
shown
act
entri
receptor
sarscov
infect
jeffer
et
al
express
lung
alveolar
liver
cell
correl
diseas
pathogenesi
observ
organ
mani
sar
patient
given
oligomannos
nglycan
may
involv
viral
attach
cell
interest
studi
effect
modif
nglycan
profil
object
possibl
identifi
therapeut
strategi
report
describ
first
complet
nglycosyl
analysi
sarscov
glycoprotein
produc
vero
cell
cell
line
deriv
african
green
monkey
demonstr
inhibitori
effect
inhibitor
nbutyldeoxynojirimycin
nbdnj
viru
replic
cell
line
viral
protein
purifi
viral
particl
separ
sdspage
gel
stain
coomassi
blue
fig
protein
n
detect
gel
dens
enough
detect
smaller
kda
e
protein
western
blot
use
sarscov
glycoprotein
antibodi
imgenex
confirm
ident
molecular
weight
kda
protein
consist
earlier
report
krokhin
et
al
song
et
al
xiao
et
al
indic
presenc
fulli
modifi
glycoprotein
appar
differ
molecular
weight
glycoprotein
produc
without
nbdnj
spike
glycoproteincontain
band
cut
gel
nglycan
analysi
ingel
pngase
f
digest
follow
hplc
deriv
exoglycosidas
digest
malditof
nanoelectrospray
msm
describ
hplc
trace
sarscov
glycan
obtain
without
nbdnj
treatment
shown
fig
trace
obtain
digest
witharthrobact
ureafacien
sialidas
fig
virtual
ident
show
neglig
incorpor
sialic
acid
glycan
previou
work
feldmann
et
al
also
shown
lack
sialyl
nglycan
marburg
viru
grown
vero
cell
posit
ion
maldi
fig
neg
ion
nanoelectrospray
spectra
similar
hplc
trace
although
glycan
resolv
mass
spectrometri
tabl
list
identifi
glycan
percentag
total
glycan
pool
measur
malditof
ms
tabl
list
percentag
variou
compound
glycan
type
glycan
differ
structur
mass
thu
separ
mass
spectrometri
figur
taken
approxim
nevertheless
reflect
composit
mixtur
reason
accur
glycan
identifi
exoglycosidas
digest
monitor
hplc
neg
ion
msm
mh
po
ion
harvey
use
electrospray
sampl
introduct
harvey
c
harvey
et
al
hplc
trace
obtain
ab
bovin
testi
btg
treatment
fig
confirm
attach
galactos
nonreduc
termini
glycan
antenna
incub
hexosaminidas
fig
reduc
profil
man
glcnac
man
glcnac
fuc
seri
unaffect
highmannos
glycan
compound
present
concentr
weak
permit
acquisit
inform
msm
spectra
howev
structur
could
deduc
structur
relat
compound
eg
complex
glycan
differ
number
galactos
residu
compound
identifi
tabl
ion
nomenclatur
follow
discuss
follow
introduc
domon
costello
modifi
harvey
et
al
use
subscript
r
specifi
cleavag
adjac
reducingtermin
glcnac
residu
specifi
cleavag
adjac
penultim
glcnac
order
avoid
confus
subscript
number
chang
function
antenna
length
highmannos
glycan
contain
four
nine
mannos
residu
present
glycan
mixtur
fig
incub
aspergillu
saitoi
amannosidas
data
shown
reduc
larger
compound
man
glcnac
compound
tabl
confirm
linkag
neg
ion
msm
spectra
highmannos
glycan
man
glcnac
phosphat
adduct
shown
fig
crossr
r
fragment
togeth
b
ion
highmass
end
spectra
defin
chitobios
core
harvey
harvey
et
al
singl
c
fragment
mz
confirm
hexos
mannos
nonreduc
end
residu
ion
toward
centr
spectrum
mainli
deriv
allow
distribut
mannos
residu
two
antenna
determin
predomin
among
ion
dion
formal
loss
c
ion
ion
crossr
cleavag
fragment
core
mannos
residu
harvey
thu
man
glcnac
produc
spectrum
ion
mz
respect
confirm
substitut
pattern
provid
c
ion
mz
three
mannos
residu
spectrum
man
glcnac
fig
ion
posit
spectrum
man
glcnac
show
sixth
mannos
attach
three
diagnost
ion
shift
mass
unit
higher
mass
spectrum
man
glcnac
fig
show
seventh
mannos
attach
high
abund
ion
mz
consist
locat
antenna
ion
term
thought
equival
ion
result
substitut
pattern
branch
mannos
mannos
core
pattern
ion
present
spectrum
man
glcnac
fig
confirm
attach
th
mannos
indic
compound
classic
pattern
final
spectrum
man
glcnac
fig
indic
presenc
second
isom
three
mannos
residu
fragment
spectrum
obtain
man
glcnac
hybrid
glycan
number
tabl
detect
mass
spectra
appar
hplc
trace
total
glycan
howev
becam
visibl
hplc
follow
incub
jack
bean
remov
mannos
residu
leav
chitobios
core
consist
glcnac
galglcnac
data
shown
fig
show
neg
ion
ms
ms
spectra
hybrid
glycan
fig
fig
pattern
mannos
substitut
determin
mass
ion
neg
ion
msm
spectra
describ
spectrum
glycan
correspond
hex
glcnac
fig
show
presenc
two
compound
evidenc
appear
two
set
ion
mz
indic
three
two
mannos
residu
respect
linkag
mannos
residu
compound
two
mannos
residu
determin
locat
fucos
posit
termin
glcnac
residu
present
determin
mass
abund
r
b
ion
msm
spectra
harvey
harvey
et
al
form
loss
fucos
residu
result
attach
elimin
neutral
fragment
structur
shown
tabl
antennasubstitut
fucos
detect
spectra
complex
glycan
composit
specifi
mass
etyp
crossr
fragment
ion
substitu
plu
mass
unit
mannos
residu
harvey
harvey
et
al
ion
low
abund
present
mz
spectrum
shown
fig
mz
fig
confirm
presenc
glcnac
galglcnac
antenna
respect
composit
defin
crossr
cleavag
ion
form
fragment
mannos
residu
appear
mass
unit
mass
substitu
link
mannos
mz
glcnaccontain
antenna
mz
galglcnac
see
fig
repres
spectra
shown
fig
bi
triand
tetraantennari
glycan
found
without
core
fucos
without
bisect
glcnac
residu
exoglycosidas
digest
ab
btg
guh
fig
show
antenna
consist
galactos
glcnac
neg
ion
msm
spectra
ident
refer
standard
branch
structur
triantennari
glycan
fig
reveal
mass
e
ion
mz
subscript
indic
origin
harvey
harvey
et
al
ion
also
present
spectrum
tetraantennari
glycan
fig
wherea
ion
spectrum
triantennari
glycan
mz
valu
respect
spectrum
biantennari
glycan
fig
move
mz
spectrum
tetraantennari
glycan
reflect
presenc
addit
galglcnac
moieti
addit
ion
mz
also
characterist
branch
structur
fucos
substitut
pattern
core
glcnac
residu
defin
mass
r
b
ion
describ
occurr
bisect
glcnac
residu
determin
presenc
abund
ion
eg
mz
fig
equival
mass
ion
correspond
compound
contain
bisect
glcnac
residu
describ
earlier
harvey
et
al
basic
complex
structur
accompani
rel
larg
amount
analogu
fewer
number
galactos
residu
tabl
confirm
incub
bovin
testi
four
repres
spectra
shown
fig
illustr
compound
contain
fucos
residu
attach
core
glcnac
shown
mass
r
b
ion
spectrum
biantennari
glycan
lack
galactos
residu
fig
contain
ion
mz
respect
consist
absenc
galactos
c
ion
z
show
glcnac
nonreduc
terminu
addit
one
galactos
residu
fig
produc
mix
spectrum
glycan
galactos
attach
either
antenna
shown
two
pair
ion
mz
major
isom
mz
two
c
ion
mz
confirm
hexos
galactos
glcnac
respect
nonreduc
terminu
ion
mz
consist
presenc
galglcnaccontain
antenna
spectra
glycan
contain
low
galactos
mixtur
interpret
postul
expect
ion
base
structur
identifi
fulli
galactosyl
compound
find
relev
diagnost
ion
spectra
thu
spectrum
compound
composit
man
glcnac
fuc
fig
would
expect
contain
contribut
bisect
biantennari
glycan
triantennari
glycan
lack
galactos
spectrum
contain
promin
ion
mz
expect
mass
e
ion
triantennari
glycan
lack
galactos
ion
mz
enhanc
rel
abund
ion
mz
suggest
presenc
small
amount
bisect
biantennari
glycan
ion
correspond
two
compound
produc
spectrum
fig
degalactosyl
tetraantennari
glycan
bisect
triantennari
compound
former
compound
produc
characterist
cov
strain
moi
incub
iminosugar
inhibitor
nbdnj
integr
vero
cell
monolay
monitor
daili
light
microscopi
nbdnj
concentr
cell
monolay
remain
intact
show
sign
virallyinduc
cytopath
effect
cpe
howev
signific
toxic
seen
drug
concentr
shown
xtt
assay
data
shown
fig
show
nphplc
profil
nglycan
spike
protein
obtain
presenc
nbdnj
concentr
protect
cell
cpe
glycan
higher
molecular
weight
observ
sampl
without
nbdnj
identifi
hplc
exoglycosidas
digest
ureafacien
sialidas
bovin
testi
pneumonia
nacetylhexosaminidas
jack
bean
bovin
kidney
glc
man
glcnac
glc
man
glcnac
glc
man
glcnac
show
nbdnj
concentr
use
abl
partial
inhibit
glycan
process
block
first
stage
name
remov
termin
glucos
residu
howev
still
abl
remov
outer
mannos
residu
give
observ
compound
although
process
block
complex
glycan
still
found
profil
like
reason
would
presenc
endomannosidas
abl
split
glc
man
enzym
report
rat
luba
spiro
luba
spiro
moor
spiro
appear
inform
possibl
occurr
african
green
monkey
howev
high
abund
peak
label
fig
account
isom
man
glcnac
lost
mannos
residu
gu
valu
fucosyl
triantennari
glycan
support
propos
although
postul
endomannosidas
activ
permit
extens
nglycan
process
product
complex
glycan
nearli
normal
profil
presenc
nbdnj
drug
prevent
format
monoglucosyl
nglycan
necessari
bind
chaperon
calnexin
calreticulin
essenti
correct
protein
fold
viral
surfac
glycoprotein
depend
interact
correct
fold
vigerust
shepherd
thu
inhibit
prevent
interact
potenti
lead
region
global
glycoprotein
misfold
therefor
observ
sarscov
glycoprotein
undergo
extens
nglycan
process
complex
structur
presenc
nbdnj
necessarili
correl
proper
glycoprotein
fold
unfortun
necessari
conform
sensit
antisarscov
antibodi
test
conclus
avail
time
studi
perform
improp
fold
induc
nbdnj
could
explain
protect
effect
drug
toward
viral
infect
abil
retain
complex
nglycan
process
could
contribut
drug
low
cytotox
studi
first
describ
fulli
rang
nglycan
present
sarscov
spike
glycoprotein
consist
mainli
highmannos
man
glcnac
total
glycan
hybrid
bi
triand
tetraantennari
complex
glycan
without
bisect
glcnac
core
fucos
complex
glycan
fewer
full
complement
galactos
residu
present
rel
high
abund
complex
glycan
carri
galactos
sialyl
neglig
evid
found
glycan
nacetyllactosamin
extens
fucos
attach
antenna
rel
high
abund
complex
glycan
lack
one
normal
galactos
residu
might
indic
involv
lectin
lsectin
viral
bind
recent
found
ebola
viru
powlesland
et
al
treatment
glucosidas
inhibitor
nbdnj
inhibit
nglycan
process
evidenc
appear
profil
glycan
composit
glc
man
glcnac
howev
complex
glycan
still
appear
glycan
profil
suggest
presenc
abl
hydrolys
glc
man
chain
allow
attach
glcnac
first
step
toward
complex
glycan
biosynthesi
protect
cell
cytopath
effect
viru
possibl
result
inhibit
glycan
process
suggest
possibl
use
glucosidas
inhibitor
treat
sarscov
infect
methanol
obtain
bdh
ltd
pool
uk
ammonium
phosphat
acid
dhb
aldrich
chemic
co
ltd
pool
water
distil
use
quartz
apparatu
nbdnj
gift
monsanto
searl
st
loui
usa
work
infecti
sarscov
perform
high
biocontain
laboratori
nation
microbiolog
laboratori
nml
public
health
agenc
canada
phac
vero
cell
atcc
kidney
epitheli
cell
deriv
african
green
monkey
cercopithecu
aethiop
cultur
dulbecco
modifi
eagl
medium
dmem
contain
fetal
bovin
serum
fb
subsequ
infect
strain
sarscov
marra
et
al
moi
without
presenc
differ
concentr
mgml
nbdnj
h
viru
adsorpt
cell
wash
time
dmem
supplement
fb
without
nbdnj
ad
fortyeight
hour
postinfect
cell
supernat
harvest
cell
clear
lowspe
centrifug
viru
particl
pellet
sucros
cushion
rpm
h
wash
pb
resuspend
inactiv
sampl
load
buffer
sd
infect
inactiv
heat
specimen
min
prior
remov
high
biocontain
vero
cell
cultur
plate
dmem
supplement
fb
confluenc
medium
remov
replac
fb
contain
variou
concentr
nbdnj
well
per
concentr
drug
cytotox
assess
day
posttreat
use
xtt
metabol
assay
roch
laval
canada
accord
manufactur
direct
sarscov
prepar
analys
polyacrylamid
gel
electrophoresi
sdspage
follow
coomassi
blue
stain
stain
protein
band
correspond
sarscov
glycoprotein
cut
gel
enzymat
digest
peptid
nglycosidas
f
pngase
f
roch
diagnost
ltd
basel
switzerland
subsequ
nglycan
analysi
see
confirm
band
select
nglycan
analysi
correspond
sarscov
glycoprotein
antisarscov
antibodi
use
western
blot
protocol
briefli
sarscov
prepar
subject
sdspage
gel
protein
transfer
pvdf
membran
use
semidri
transfer
techniqu
membran
block
milk
solut
phosphatebuff
salin
pb
overnight
incub
mous
antisar
clone
imgenex
ca
usa
dilut
milk
solut
room
temperatur
least
h
membran
wash
three
time
h
incub
room
temperatur
horseradish
peroxidas
hrp
conjug
goat
antimous
secondari
antibodi
sigma
chemic
dilut
milk
solut
membran
wash
three
time
pb
sarscov
glycoprotein
band
detect
develop
membran
use
ecl
western
blot
detect
kit
amersham
bioscienc
littl
chalfont
uk
accord
manufactur
instruct
follow
exposur
xray
film
clx
posur
film
pierc
procedur
essenti
follow
describ
et
al
glycoprotein
separ
sdspage
biorad
miniprotean
ii
apparatu
mm
plate
resolv
gel
develop
gel
stain
coomassi
blue
sarscov
glycoprotein
gel
band
excis
gel
cut
piec
mm
wash
mm
nahco
bdh
limit
pool
uk
soak
buffer
min
procedur
repeat
twice
third
wash
mm
dithiothreitol
ad
incub
min
reduc
disulfid
bond
iodoacetamid
mm
ad
solut
incub
min
dark
vv
solut
aqueou
mm
nahco
ph
ad
incub
min
follow
vacuum
dri
pngase
f
ec
ml
uml
roch
diagnost
ltd
nahco
buffer
enough
cover
gel
ad
dri
gel
piec
incub
h
overnight
supernat
retain
gel
wash
twice
water
acetonitril
riedel
de
laboratori
seelz
germani
wash
collect
desalt
incub
h
activ
centrifug
supernat
filter
millipor
lh
hydrophil
ptfe
syringetip
filter
vacuum
dri
prepar
direct
mass
spectrometr
analysi
label
follow
hplc
analysi
sampl
mass
spectrometr
analysi
clean
drop
dialysi
nafion
membran
et
al
glycan
label
reduct
amin
bigg
et
al
use
label
kit
glyko
part
prozym
hayward
ca
usa
label
solut
prepar
accord
manufactur
instruct
store
five
microlit
solut
ad
dri
sugar
incub
h
residu
reagent
remov
ascend
paper
chromatographi
mm
chromatographi
paper
millipor
watford
uk
acetonitril
h
sampl
view
uv
light
spot
correspond
label
sugar
cut
paper
sugar
elut
use
four
sequenti
aliquot
water
ml
nitric
acidwash
glass
tube
elut
nglycan
vacuum
dri
redissolv
water
one
two
picomol
nglycan
vacuum
dri
incub
h
mm
sodium
citrat
buffer
ph
exoglycosidas
glyko
follow
arthrobact
ureafacien
sialidas
ab
ec
mixtur
ab
bovin
testi
btg
ec
mixtur
ab
btg
streptococcu
pneumonia
nacetylhexosaminidas
guh
ec
manufactur
recommend
concentr
second
experi
glycan
incub
jack
bean
mannosidas
jbm
ec
uml
aspergillu
saitoi
asm
muml
enzym
remov
exoglycosidas
digest
use
wash
water
centrifug
rpm
min
nitrocellulos
microspin
filter
radley
saffron
walden
uk
sampl
ad
filter
centrifug
rpm
min
digest
tube
wash
water
transfer
filter
centrifug
rpm
min
filter
rins
water
centrifug
rpm
min
collect
solut
vacuum
dri
redissolv
water
analysi
hplc
acetonitril
ad
sampl
examin
normalphas
np
hplc
system
water
allianc
water
corpor
milford
usa
fit
glycosep
n
column
oxford
glycosci
abingdon
uk
run
time
min
guil
et
al
nlink
sugar
elut
column
retent
time
min
comparison
dextran
ladder
allow
assign
glucos
unit
gu
valu
peak
facilit
identif
glycan
present
releas
pool
posit
ion
malditof
mass
spectra
obtain
watersm
technolog
tofspec
reflectron
tof
mass
spectromet
water
ltd
manchest
puls
acceler
voltag
kv
respect
data
acquisit
process
perform
masslynx
softwar
version
sampl
prepar
mix
aqueou
solut
sampl
satur
solut
dhb
acetonitril
stainless
steel
maldi
target
allow
mixtur
dri
ambient
condit
dri
sampl
spot
redissolv
ethanol
allow
dri
electrospray
mass
spectrometri
perform
water
quadrupoletimeofflight
qtof
ultima
global
instrument
neg
ion
mode
sampl
v
v
methanol
water
infus
proxeon
nanospray
capillari
proxeon
biosystem
odens
denmark
ion
sourc
condit
follow
temperatur
nitrogen
flow
lh
infus
needl
potenti
kv
cone
voltag
v
voltag
v
spectra
scan
acquir
digit
rate
ghz
accumul
satisfactori
signal
nois
ratio
obtain
major
ion
mh
po
phosphat
appar
aris
residu
phosphat
origin
sampl
observ
previous
glycan
sampl
releas
msm
data
acquisit
parent
ion
select
low
resolut
mz
mass
window
allow
transmiss
isotop
peak
fragment
argon
pressur
record
instrument
pressur
gaug
mbar
voltag
collis
cell
adjust
mass
charg
give
even
distribut
fragment
ion
across
mass
scale
typic
valu
v
voltag
recommend
manufactur
instrument
control
data
acquisit
process
perform
masslynx
softwar
version
display
spectra
smoother
use
savitzki
golay
algorithm
abund
background
ion
mz
remov
clariti
thank
wellcom
trust
biotechnolog
biolog
scienc
research
council
equip
grant
purchas
qtof
tofspec
mass
spectromet
respect
thank
public
health
agenc
canada
phac
financi
support
tabl
key
structur
symbol
legend
fig
addit
glucos
glycan
type
colour
blue
high
mannos
orang
hybrid
purpl
monoantennari
red
biantennari
green
triantennari
pink
tetraantennari
tabl
three
glycan
residu
glucos
residu
highlight
